Evidence map›Paper›PMID 25919140›Full record

ArticlePloS one2015

High EMT Signature Score of Invasive Non-Small Cell Lung Cancer (NSCLC) Cells Correlates with NFκB Driven Colony-Stimulating Factor 2 (CSF2/GM-CSF) Secretion by Neighboring Stromal Fibroblasts.

Albin Rudisch, Matthew Richard Dewhurst, Luminita Gabriela Horga, Nina Kramer, Nathalie Harrer, Meng Dong, Heiko van der Kuip, Andreas Wernitznig, Andreas Bernthaler, Helmut Dolznig and 1 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
2.9field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 42 citations in OpenAlex.

  1. Review
  2. Article
  3. The Significance of CXCL1 in Cancer: An Overview of Molecular Mechanisms.International journal of molecular sciences · 2026
    Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Radiation oncology (London, England) · 2020
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 2 countries.

Albin RudischDepartment of Lead Discovery, Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria; Department of Microbiology, Immunobiology and Genetics, Center of Molecular Biology, Max F. Perutz Laboratories, University of Vienna, Vienna, Austria.
Matthew Richard DewhurstDepartment of Lead Discovery, Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.
Luminita Gabriela HorgaDepartment of Lead Discovery, Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.
Nina KramerInstitute of Medical Genetics, Medical University of Vienna, Vienna, Austria.
Nathalie HarrerDepartment of Lead Discovery, Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.
Meng DongDr. Margarete Fischer-Bosch Institute of Clinical Pharmacology and University of Tübingen, Stuttgart, Baden-Württemberg, Germany.
Heiko van der KuipDr. Margarete Fischer-Bosch Institute of Clinical Pharmacology and University of Tübingen, Stuttgart, Baden-Württemberg, Germany.
Andreas WernitznigDepartment of Lead Discovery, Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.
Andreas BernthalerDepartment of Lead Discovery, Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.
Helmut DolznigInstitute of Medical Genetics, Medical University of Vienna, Vienna, Austria.
Wolfgang SommergruberDepartment of Lead Discovery, Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.
Boehringer Ingelheim (Austria) · ATMedical University of Vienna · ATDr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology · DEMax Perutz Labs · ATUniversity of Tübingen · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We established co-cultures of invasive or non-invasive NSCLC cell lines and various types of fibroblasts (FBs) to more precisely characterize the molecular mechanism of tumor-stroma crosstalk in lung cancer. The HGF-MET-ERK1/2-CREB-axis was shown to contribute to the onset of the invasive phenotype of Calu-1 with HGF being secreted by FBs. Differential expression analysis of the respective mono- and co-cultures revealed an upregulation of NFκB-related genes exclusively in co-cultures with Calu-1. Cytokine Array- and ELISA-based characterization of the "cytokine fingerprints" identified CSF2 (GM-CSF), CXCL1, CXCL6, VEGF, IL6, RANTES and IL8 as being specifically upregulated in various co-cultures. Whilst CXCL6 exhibited a strictly FB-type-specific induction profile regardless of the invasiveness of the tumor cell line, CSF2 was only induced in co-cultures of invasive cell lines regardless of the partnered FB type. These cultures revealed a clear link between the induction of CSF2 and the EMT signature of the cancer cell line. The canonical NFκB signaling in FBs, but not in tumor cells, was shown to be responsible for the induced and constitutive CSF2 expression. In addition to CSF2, cytokine IL6, IL8 and IL1B, and chemokine CXCL1 and CXCL6 transcripts were also shown to be increased in co-cultured FBs. In contrast, their induction was not strictly dependent on the invasiveness of the co-cultured tumor cell. In a multi-reporter assay, additional signaling pathways (AP-1, HIF1-α, KLF4, SP-1 and ELK-1) were found to be induced in FBs co-cultured with Calu-1. Most importantly, no difference was observed in the level of inducibility of these six signaling pathways with regard to the type of FBs used. Finally, upon tumor fibroblast interaction the massive induction of chemokines such as CXCL1 and CXCL6 in FBs might be responsible for increased recruitment of a monocytic cell line (THP-1) in a transwell assay.

Indexed as

AnimalsCadherinsCarcinoma, Non-Small-Cell LungCell CommunicationCell Line, TumorCytokinesDermisEpithelial-Mesenchymal TransitionFibroblastsGene Expression ProfilingGene Expression Regulation, NeoplasticGene Regulatory NetworksGenes, ReporterGranulocyte-Macrophage Colony-Stimulating FactorHepatocyte Growth FactorHumansCadherinsCytokinesGranulocyte-Macrophage Colony-Stimulating FactorHepatocyte Growth FactorKLF4 protein, humanKlf4 protein, ratKruppel-Like Factor 4NF-kappa BProto-Oncogene Proteins c-metRNA, Messenger

Identifiers

PMID25919140
PMCPMC4412534
OpenAlexW2028058217

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.